IMAGENEBIO INC.

ImageneBio shareholders approved a revision of the 2025 Equity Incentive Plan that increases the number of shares issuable by 850,000 and will henceforth include convertible preferred shares and prepaid warrants in the annual automatic increase. At the annual meeting, David P. Bonita and Joseph P. Slattery were elected as Class II directors until the 2029 annual meeting; PricewaterhouseCoopers was reappointed as independent auditor for the fiscal year ending December 31, 2026. The company also entered a securities purchase agreement for a private placement of about $30 million, covering the sale of prepaid warrants for up to 5,770,335 common shares, led by Coastlands Capital with Leerink as placement agent. » More on de.investing.com

ImageneBio reported for the quarter ended Dec. 31, 2025, earnings per share of $1.27, after -$2.28 in the prior year. For the full year the company posted a loss per share of $9.64, after -$12.24 a year earlier. The quarter shows an improvement year over year, but the annual result remains negative. » More on finanzen.net

ImageneBio has appointed Dr. Ben Porter-Brown as chief medical officer. He brings more than 20 years of experience in the clinical development of autoimmune and inflammatory diseases and previously led clinical development at MoonLake Immunotherapeutics as well as programs for OX40/OX40L inhibitors. At ImageneBio he will lead the clinical organization and be responsible for conducting the phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis, which is planned to be expanded to sites in the UK and Europe. Dr. Porter-Brown will assume his role on 16 February 2026. » More on de.investing.com